266.90

1.53% -4.14

Iqvia Holdings Inc (IQV)

Overview News Price History Option Chain Financials Discussions Forecast

Iqvia Holdings Inc stock is traded at $266.90, with a volume of 1.04M. It is down -1.53% in the last 24 hours and down -0.71% over the past month. Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

Previous Close:

$271.04

Open:

$271.92

24h Volume:

1.04M

Relative Volume:

0.85

Market Cap:

$43.93B

Revenue:

$16.63B

Net Income/Loss:

$1.39B

P/E Ratio:

33.08

EPS:

8.0674

Net Cash Flow:

$2.12B

1W Performance:

+2.70%

1M Performance:

-0.71%

6M Performance:

+55.22%

1Y Performance:

+29.72%

1-Day Range:

$263.21

$272.98

1-Week Range:

$257.30

$272.98

52-Week Range:

$154.50

$277.40

Iqvia Holdings Inc Stock (IQV) Company Profile

Name

Iqvia Holdings Inc

Sector

Healthcare (1052)

Industry

Diagnostics & Research (44)

Phone

919-998-2000

Address

2400 ELLIS ROAD, DURHAM, NC

Employee

93,000

Twitter

@IQVIA_global

Next Earnings Date

2026-10-27

Latest SEC Filings

IQV's Discussions on Twitter

Compare IQV vs TMO, DHR, NTRA, A, IDXX

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IQV Iqvia Holdings Inc	266.90	43.93B	16.63B	1.39B	2.12B	8.0674
TMO Thermo Fisher Scientific Inc	690.00	255.13B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	229.04	161.01B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	393.44	56.71B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	172.97	48.77B	7.23B	1.41B	1.09B	4.979
IDXX Idexx Laboratories Inc	560.36	44.15B	4.45B	1.10B	1.06B	13.59

Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-26	Resumed	UBS	Buy
Jun-17-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-09-26	Upgrade	TD Cowen	Hold → Buy
Mar-06-26	Upgrade	Barclays	Equal Weight → Overweight
Mar-03-26	Initiated	RBC Capital Mkts	Outperform
Dec-02-25	Resumed	Morgan Stanley	Overweight
Nov-13-25	Initiated	BMO Capital Markets	Outperform
Nov-03-25	Downgrade	TD Cowen	Buy → Hold
Oct-29-25	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-09-25	Upgrade	HSBC Securities	Hold → Buy
Sep-09-25	Upgrade	Jefferies	Hold → Buy
Apr-25-25	Downgrade	HSBC Securities	Buy → Hold
Apr-10-25	Downgrade	Barclays	Overweight → Equal Weight
Feb-03-25	Downgrade	BTIG Research	Buy → Neutral
Dec-20-24	Initiated	Stephens	Overweight
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Initiated	RBC Capital Mkts	Outperform
Jul-24-24	Downgrade	Jefferies	Buy → Hold
Jun-06-24	Initiated	Goldman	Buy
Feb-26-24	Initiated	Leerink Partners	Outperform
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Feb-13-24	Initiated	BTIG Research	Buy
Nov-02-23	Downgrade	Robert W. Baird	Outperform → Neutral
Sep-06-23	Initiated	HSBC Securities	Buy
Mar-17-23	Initiated	Truist	Buy
Dec-06-22	Initiated	Cowen	Outperform
Nov-17-22	Downgrade	Citigroup	Buy → Neutral
Aug-25-22	Initiated	Credit Suisse	Outperform
Jul-15-22	Initiated	SVB Leerink	Outperform
May-24-22	Initiated	Guggenheim	Buy
Apr-29-22	Upgrade	Piper Sandler	Neutral → Overweight
Apr-25-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Aug-05-21	Resumed	Credit Suisse	Outperform
Apr-16-21	Upgrade	Stephens	Equal-Weight → Overweight
Mar-08-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-03-21	Initiated	Barclays	Overweight
Jul-07-20	Initiated	Stephens	Equal-Weight
Mar-02-20	Initiated	Deutsche Bank	Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Dec-13-19	Upgrade	CFRA	Sell → Hold
Nov-14-19	Upgrade	Wolfe Research	Peer Perform → Outperform
Jun-21-19	Upgrade	Mizuho	Neutral → Buy
May-28-19	Initiated	SVB Leerink	Outperform
Jan-18-19	Upgrade	Jefferies	Hold → Buy
Oct-09-18	Initiated	UBS	Buy
Oct-02-18	Reiterated	Robert W. Baird	Outperform
Jul-25-18	Upgrade	BofA/Merrill	Neutral → Buy
Jul-25-18	Reiterated	Stifel	Buy
Jul-03-18	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-18	Upgrade	Goldman	Neutral → Buy
Mar-07-18	Upgrade	SunTrust	Hold → Buy
Jan-19-18	Initiated	Evercore ISI	Outperform

View All

Iqvia Holdings Inc Stock (IQV) Latest News

Oct 15, 2026

Stifel lifts target for IQVIA Holdings stock to USD 303.00 - ad-hoc-news.de

Oct 15, 2026

IQVIA Holdings (IQV) Gains as Improving Demand Environment and High Win Rates - Yahoo Finance

Oct 15, 2026

Deutsche Bank Adjusts IQVIA Holdings Price Target to $179 From $191 - marketscreener.com

Oct 15, 2026

Oct 14, 2026

VEEV Expands IQVIA Partnership With Clinical Operations Software Suite - Zacks Investment Research

Oct 14, 2026

VEEV Expands IQVIA Partnership With Clinical Operations Software Suite - TradingView

Oct 14, 2026

Stifel Nicolaus Adjusts IQVIA Holdings Price Target to $303 From $276 - Yahoo Finance

Oct 14, 2026

JPMorgan Adjusts Price Target on IQVIA Holdings to $295 From $285 - www.marketscreener.com

Oct 14, 2026

JPMorgan Adjusts Price Target on IQVIA Holdings to $295 From $285 - Yahoo Finance

Oct 14, 2026